According to a recent LinkedIn post from F-Prime, the firm is leading a $10 million seed round for Almanac Health, a clinical artificial intelligence platform emerging from stealth. The post indicates that Almanac aims to provide research-validated, specialist-grade clinical decision support at the point of care and to integrate with existing electronic health record systems.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post highlights that Almanac Health’s founder and CEO, Cyril Zakka, M.D., previously published an NEJM AI paper introducing retrieval-augmented generation to clinical medicine, a technique associated with OpenEvidence. For investors, this association with peer-reviewed research and EHR integration suggests potential differentiation in a crowded clinical AI market, which could enhance F-Prime’s exposure to healthcare AI adoption trends.
The post suggests that Almanac’s focus on safety, validation, and workflow integration may position it to benefit from growing demand for AI tools that support clinicians without disrupting care delivery. If the platform gains traction with health systems and specialists, F-Prime’s lead role in the seed round could translate into upside from both technology commercialization and broader enterprise healthcare IT spending shifts toward AI-enabled decision support.